WEE1 Kinase Inhibitor Improved PFS in TP53-Mutated Ovarian Cancer

July 8, 2020 5:00 am

Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.

By Leah Lawrence

Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared … Read more